Scarica l'app Stockscreener
1.82
5.81%
0.10
Dopo l'orario di chiusura:
1.82
Precedente Chiudi:
$1.72
Aprire:
$1.73
Volume 24 ore:
524.48K
Relative Volume:
1.12
Capitalizzazione di mercato:
$191.73M
Reddito:
$7.05M
Utile/perdita netta:
$-30.43M
Rapporto P/E:
-4.8046
EPS:
-0.3788
Flusso di cassa netto:
$21.84M
1 W Prestazione:
+2.25%
1M Prestazione:
+24.66%
6M Prestazione:
-16.89%
1 anno Prestazione:
+4.60%
Intervallo 1D:
$1.73
$1.85
Intervallo di 1 settimana:
$1.71
$1.955
Portata 52W:
$1.07
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Compare PRQR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.82 | 191.73M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | Oppenheimer | Outperform |
| 2025-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-29 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
Breakout Zone: Is ProQR Therapeutics NV attractive for institutional investors2026 Opening Moves & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Wall Street Zen - MarketBeat
ProQR Therapeutics NV earnings beat by €0.02, revenue topped estimates - Investing.com Nigeria
ProQR Therapeutics (NASDAQ:PRQR) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Citizens reiterates ProQR Therapeutics stock rating on RNA editing platform potential - Investing.com
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated at Oppenheimer - MarketBeat
ProQR Therapeutics Q4 2025 Financial Results: Loss of $9.1MNews and Statistics - IndexBox
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
ProQR: Q4 Earnings Snapshot - WHAS11
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027 - TipRanks
ProQR (PRQR) Advances Clinical Trials Amid Reduced Cash Holdings - GuruFocus
ProQR Therapeutics (NASDAQ: PRQR) details 2025 loss, cash runway and RNA editing focus - Stock Titan
Biotech ProQR ends 2025 with €92.4M cash, eyes key trial readout in 2026 - Stock Titan
ProQR: Fourth Quarter Financial Overview - Bitget
Analysts Set ProQR Therapeutics Price Target at $7.14 - National Today
ProQR Therapeutics NV expected to post a loss of 10 cents a shareEarnings Preview - TradingView
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Quarterly Risk: Can ProQR Therapeutics NV weather a recession2025 Big Picture & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Weekly Trades: Is ProQR Therapeutics NV backed by strong institutional buyingJuly 2025 Pullbacks & Verified Momentum Stock Alerts - baoquankhu1.vn
Highs Report: Is ProQR Therapeutics NV a strong candidate for buy and holdMarket Growth Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
Portfolio Shifts: Can ProQR Therapeutics NV benefit from deglobalization2025 Market Sentiment & AI Forecasted Stock Moves - baoquankhu1.vn
Is ProQR Therapeutics NV backed by strong institutional buyingWeekly Trend Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Retinitis Pigmentosa Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - Barchart.com
ProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference - 富途牛牛
Surprises Report: Is ProQR Therapeutics NV a potential multi baggerWeekly Market Summary & Expert Approved Trade Ideas - baoquankhu1.vn
PRQR Should I Buy - Intellectia AI
Retail Trends: Is ProQR Therapeutics NV a potential multi baggerJuly 2025 Momentum & Risk Managed Investment Signals - baoquankhu1.vn
Aberdeen Group plc Grows Position in ProQR Therapeutics N.V. $PRQR - Defense World
Can ProQR Therapeutics N.V. weather a recession2025 Fundamental Recap & Low Drawdown Momentum Ideas - mfd.ru
ProQR Therapeutics (PRQR) Leadership to Discuss Company Developm - GuruFocus
Aug Shorts: Is ProQR Therapeutics NV stock a buy or sellProfit Target & High Return Stock Watch Alerts - baoquankhu1.vn
How interest rate cuts could boost ProQR Therapeutics N.V. stockProfit Target & Real-Time Buy Signal Notifications - mfd.ru
What’s the RSI of ProQR Therapeutics N.V. stock2025 Big Picture & Community Verified Trade Alerts - mfd.ru
ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Up 47.2% in January - MarketBeat
Can ProQR Therapeutics N.V. withstand a market correctionCPI Data & Community Verified Watchlist Alerts - mfd.ru
Is ProQR Therapeutics N.V. currently under institutional pressureChart Signals & Long-Term Growth Portfolio Plans - mfd.ru
PRQR PE Ratio & Valuation, Is PRQR Overvalued - Intellectia AI
Will ProQR Therapeutics N.V. stock recover after earningsPortfolio Gains Summary & Weekly High Conviction Trade Ideas - mfd.ru
A | Is ProQR Therapeutics N.V. stock showing strong momentumJuly 2025 Levels & Risk Controlled Swing Alerts - mfd.ru
Aug Levels: Is ProQR Therapeutics NV stock a buy or sellJuly 2025 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ProQR announces board changes as two members set to depart By Investing.com - Investing.com Canada
ProQR announces board changes as two members set to depart - Investing.com
ProQR Therapeutics (PRQR) Announces Board Changes at Upcoming AG - GuruFocus
ProQR Announces Planned Changes to Board Composition - markets.businessinsider.com
ProQR Therapeutics Plans Board Changes as Co-Founder and Director Exit at 2026 AGM - TipRanks
Myriad Genetics (NASDAQ:MYGN) & ProQR Therapeutics (NASDAQ:PRQR) Head-To-Head Survey - Defense World
ProQR Aktie: Pipeline-Fortschritte - Börse Global
Risk Recap: Will ProQR Therapeutics NV stock recover after earningsJuly 2025 Highlights & Capital Efficient Trading Techniques - baoquankhu1.vn
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):